Silver Book Fact

t-PA cost savings

The total annual benefit to society from t-PA use in the United States is around $363 million—$60 million in direct cost savings to society plus an additional 7,510 QALYs. This means that t-PA saves $6,074 and adds 0.75 QALY per use.

Johnston, SC. The Economic Case for New Stroke Thrombolytics. Stroke. 2010; 41(10): S59-62. http://stroke.ahajournals.org/cgi/content/short/41/10_suppl_1/S59

Reference

Title
The Economic Case for New Stroke Thrombolytics
Publication
Stroke
Publication Date
2010
Authors
Johnston, SC.
Volume & Issue
Volume 41, Issue 10
Pages
S59-62
URL
Read Full Resource

Categories

  • Innovative Medical Research
  • Economic Value

Related Facts

  • Per-patient annual cost of treating stroke in atrial fibrillation patients
    The per-patient annual cost of treating stroke in atrial fibrillation patients was found to be $1,485 in a wellcontrolled anti-coagulation clinic, $3,710 for those receiving warfarin in routine medical care,…  
  • Atrial fibrillation ablation prevents recurrence of AFib
    Atrial fibrillation ablation, which involves using a catheter inserted into the heart to destroy electrical conduction tissue in or near the atria, prevents the recurrence of atrial fibrillation in up…  
  • Decrease in AFib hospitalization rates
    The use of practice guidelines in atrial fibrillation patients saw a decrease in rate of hospitalization from 74%to 38%.  
  • Effect of optimal anticoagulation
    If 50% of atrial fibrillation patients who currently receive warfarin in routine medical care were optimally anticoagulated, 9,852 emboli would be prevented and $1.3 billion would be saved each year.  
  • Stroke prevention through optimal anticoagulation
    If half of atrial fibrillation patients who currently receive warfarin in a routine care setting had their anti-coagulation optimized, around 9,000 strokes and more than 29,000 bleeds would be prevented.